Standard Biotools Inc (LAB) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Standard Biotools Inc stock $0.79, price $0.64, upside +23.4%, quality 30 out of 100. Rating: undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range $0.6000 – $7.22 · fair‑value band $0.5200 – $0.9800 · the $0.6400 price screens below the $0.7900 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Standard Biotools in your weekly email
Every Wednesday you see whether Standard Biotools is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific.
Show moreShow less
The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses.
The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications.
The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies.
It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001.
Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
Stock analysis
Standard Biotools Inc (LAB) currently trades at $0.6400, while our model-based Fair Value estimate is $0.7900, implying the stock looks roughly 19% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $0.5200 (bear) to $0.9800 (bull), the price of $0.6400 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Standard Biotools Inc reported revenue of $85.3M in FY2025 versus $131M in FY2021, a compound −10.1%/yr. Reported net income was −$74.9M in FY2025.
Key figures
Market cap $250M Micro · P/S ratio 2.91 · EPS (TTM) $−0.0900 · Net margin −87.8% · Return on equity −7.8% · Return on assets (EBIT) −24.6% (5-year average) · Operating margin −41.8% · Revenue (TTM) $84.4M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (medium confidence).
What moves the price
The share trades about 62% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 23%, LAB screens cheaper than that median.
Fair Value models
Bear$0.5200Fair Value $0.7900Bull$0.9800
Price $0.6400 · Upside +23.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Plus 15 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.19/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−51.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.2%
Start year 2020 (pandemic). Over 10 years: −2.9% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−36.9% (2020) → −109.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks
Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score30 · Bottom 25%
Fair Value upside+23.4% · Top 25%
Profitability
Return on assets−13.2% · Bottom 25%
Net margin (12 months)157.6% · Top 25%
Operating margin (12 months)−41.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−0.9% · Bottom 25%
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Standard Biotools Inc (LAB) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $0.7900 versus a price of $0.6400, about +23% upside (undervalued).
What is the fair value of LAB?
Our model-based fair value for Standard Biotools Inc is $0.7900 (as of Nov 6, 2026), built from audited fundamentals. The current price: $0.6400.
What is the quality score of LAB?
Standard Biotools Inc has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Standard Biotools Inc (LAB)?
Our model-based price target is the fair value of $0.7900 (as of Nov 6, 2026) from 1 valuation models. Cautious scenario $0.5200, optimistic scenario $0.9800. It is a calculation from audited fundamentals, not an analyst target.
What is the Standard Biotools Inc stock forecast for 2026?
Our models put fair value at $0.7900, about +23% upside versus a price of $0.6400 (undervalued). Cautious scenario $0.5200, optimistic scenario $0.9800. The calculation is refreshed regularly with new filings.
What is the revenue of Standard Biotools Inc (LAB)?
Standard Biotools Inc reported trailing-twelve-month revenue of about $84.4M (latest available figure, as of Nov 6, 2026).
What is the intrinsic value of Standard Biotools Inc (LAB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Standard Biotools Inc it is $0.7900 per share (as of Nov 6, 2026), against a price of $0.6400. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Standard Biotools Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, LAB trades below its calculated fair value: price $0.6400, fair value $0.7900, a gap of about +23% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LAB?
No. The price is what the market pays today ($0.6400); the fair value is what the company's own numbers justify ($0.7900). For Standard Biotools Inc the two are $0.1500 per share apart. That gap is exactly why we show both numbers side by side.
How much is Standard Biotools Inc worth?
The market values Standard Biotools Inc at about $250M (market capitalisation, as of Nov 6, 2026). Per share that is $0.6400; our models calculate a fair value of $0.7900 per share.
What do the bullish and bearish scenarios say about LAB?
Our models span a range for Standard Biotools Inc: cautious scenario $0.5200, base $0.7900, optimistic $0.9800 per share (as of Nov 6, 2026, price $0.6400). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Standard Biotools Inc (LAB)?
Balance-sheet figures for Standard Biotools Inc (as of Nov 6, 2026): return on equity −7.8%, debt of 0.00 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is LAB from its 52-week high?
Standard Biotools Inc trades at $0.6400, about 62% below its 52-week high of $1.68 and 7% above the low of $0.6000 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.7900 is for.
Which stocks are comparable to Standard Biotools Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Standard Biotools Inc stock attractive at the current price?
The data as of Nov 6, 2026: price $0.6400, calculated fair value $0.7900 (+23%), Quality Score 30/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LAB calculated?
We run Standard Biotools Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $0.7900 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Standard Biotools Inc currently trades 19% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Standard Biotools Inc (LAB)?
The closing price on Nov 6, 2026 was $0.6400. Our model-based fair value is $0.7900, about +23% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Standard Biotools Inc right now?
A fairly wide model range ($0.5200 to $0.9800) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Standard Biotools Inc
How large is the market capitalisation of Standard Biotools Inc (LAB)?
The market capitalisation of Standard Biotools Inc is $250M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Standard Biotools Inc (LAB)?
The price-to-sales ratio of Standard Biotools Inc is 2.91 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Standard Biotools Inc (LAB)?
Earnings per share at Standard Biotools Inc are $−0.0900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Standard Biotools Inc (LAB)?
The net margin of Standard Biotools Inc is −87.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Standard Biotools Inc (LAB)?
The return on equity (ROE) of Standard Biotools Inc is −7.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Standard Biotools Inc (LAB)?
On an EBIT basis the return on assets of Standard Biotools Inc is −24.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Standard Biotools Inc (LAB)?
The operating margin of Standard Biotools Inc is −41.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Standard Biotools Inc (LAB)?
Revenue at Standard Biotools Inc is growing −0.9% versus a year earlier (3y avg −4.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Standard Biotools Inc (LAB) generate?
The free cash flow of Standard Biotools Inc is −$82.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Standard Biotools Inc (LAB) hold?
Standard Biotools Inc holds more cash than debt, $87.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Standard Biotools Inc in the live analysis
One click puts Standard Biotools Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 6, 2026
